Curio Wealth LLC Takes $36,000 Position in Aflac Incorporated (NYSE:AFL)

Curio Wealth LLC bought a new stake in shares of Aflac Incorporated (NYSE:AFL) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 350 shares of the financial services provider’s stock, valued at approximately $36,000.

Several other institutional investors also recently made changes to their positions in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Aflac by 6.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 4,694,511 shares of the financial services provider’s stock worth $524,846,000 after buying an additional 281,148 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Aflac by 1.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 3,226,681 shares of the financial services provider’s stock worth $333,768,000 after buying an additional 47,119 shares in the last quarter. Amundi grew its holdings in Aflac by 81.1% in the 4th quarter. Amundi now owns 2,753,513 shares of the financial services provider’s stock worth $285,181,000 after buying an additional 1,232,683 shares in the last quarter. Guinness Asset Management LTD grew its holdings in Aflac by 5.2% in the 4th quarter. Guinness Asset Management LTD now owns 2,395,045 shares of the financial services provider’s stock worth $247,682,000 after buying an additional 118,720 shares in the last quarter. Finally, Assetmark Inc. grew its holdings in Aflac by 2.0% in the 4th quarter. Assetmark Inc. now owns 1,616,772 shares of the financial services provider’s stock worth $167,239,000 after buying an additional 32,220 shares in the last quarter. 67.44% of the stock is owned by institutional investors.

Aflac Price Performance

AFL opened at $108.47 on Tuesday. The firm has a market capitalization of $59.29 billion, a P/E ratio of 11.30, a PEG ratio of 3.24 and a beta of 0.93. The stock has a fifty day moving average of $105.51 and a 200-day moving average of $107.67. The company has a quick ratio of 0.08, a current ratio of 0.10 and a debt-to-equity ratio of 0.29. Aflac Incorporated has a 12-month low of $79.31 and a 12-month high of $115.50.

Aflac (NYSE:AFL) last issued its earnings results on Wednesday, February 5th. The financial services provider reported $1.56 EPS for the quarter, missing the consensus estimate of $1.63 by ($0.07). Aflac had a return on equity of 16.20% and a net margin of 28.76%. Equities analysts forecast that Aflac Incorporated will post 6.88 EPS for the current fiscal year.

Insider Transactions at Aflac

In related news, Director Joseph L. Moskowitz sold 1,000 shares of the stock in a transaction on Friday, March 7th. The stock was sold at an average price of $107.63, for a total transaction of $107,630.00. Following the completion of the sale, the director now directly owns 25,393 shares in the company, valued at approximately $2,733,048.59. This trade represents a 3.79 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Audrey B. Tillman sold 24,744 shares of the stock in a transaction on Friday, December 27th. The stock was sold at an average price of $103.40, for a total value of $2,558,529.60. Following the sale, the executive vice president now owns 222,618 shares of the company’s stock, valued at approximately $23,018,701.20. This represents a 10.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 55,546 shares of company stock valued at $5,863,616 over the last quarter. Company insiders own 0.90% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Piper Sandler cut their target price on Aflac from $122.00 to $118.00 and set an “overweight” rating for the company in a research report on Friday, February 7th. StockNews.com upgraded Aflac from a “sell” rating to a “hold” rating in a research report on Friday, February 14th. Morgan Stanley upped their target price on Aflac from $98.00 to $105.00 and gave the stock an “equal weight” rating in a research report on Friday, February 28th. BMO Capital Markets assumed coverage on Aflac in a research report on Thursday, January 23rd. They issued a “market perform” rating and a $111.00 target price for the company. Finally, Wells Fargo & Company cut their target price on Aflac from $104.00 to $102.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 19th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $103.36.

Aflac Company Profile

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.